Korro Bio, Inc. (KRRO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Korro Bio, Inc. (KRRO) has a cash flow conversion efficiency ratio of -0.134x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.07 Million) by net assets ($119.63 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see KRRO stock market capitalisation for the company's overall valuation and market capitalisation.
Korro Bio, Inc. - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Korro Bio, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Korro Bio, Inc. stock price for real-time trading data and today's change.
Korro Bio, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Korro Bio, Inc. ranked by their cash flow conversion efficiency. Review cash generation quality of Korro Bio, Inc. to assess how much free cash flow the company generates relative to operating cash flow.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fasadgruppen Group AB
ST:FG
|
0.124x |
|
Bank Windu Kentjana Int
JK:MCOR
|
0.051x |
|
Asia Plus Group Holdings PCL
BK:ASP
|
0.253x |
|
Ferronordic AB (publ)
ST:FNM
|
0.151x |
|
SOTKAMO SILVER AB NAM.
F:VSO
|
0.214x |
|
Melnick Even Desenvolvimento Imobiliário S.A
SA:MELK3
|
-0.002x |
|
Surya Toto Indonesia Tbk
JK:TOTO
|
0.018x |
|
Seoho Electric Co.Ltd
KQ:065710
|
0.039x |
Annual Cash Flow Conversion Efficiency for Korro Bio, Inc. (2017–2025)
The table below shows the annual cash flow conversion efficiency of Korro Bio, Inc. from 2017 to 2025. Also see KRRO asset base for a full breakdown of the balance sheet.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $51.44 Million | $-78.56 Million | -1.527x | -307.82% |
| 2024-12-31 | $160.41 Million | $-60.07 Million | -0.374x | +5.43% |
| 2023-12-31 | $169.91 Million | $-67.28 Million | -0.396x | -173.10% |
| 2022-12-31 | $-99.03 Million | $-53.65 Million | 0.542x | +320.81% |
| 2021-12-31 | $130.82 Million | $-32.09 Million | -0.245x | -4.50% |
| 2020-12-31 | $192.49 Million | $-45.19 Million | -0.235x | -214.83% |
| 2019-12-31 | $167.36 Million | $34.22 Million | 0.204x | -46.55% |
| 2018-12-31 | $-44.51 Million | $-17.02 Million | 0.382x | -22.42% |
| 2017-12-31 | $-29.64 Million | $-14.61 Million | 0.493x | -- |
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate … Read more